



In the Claims

1. (Cancelled)
2. (Cancelled)
3. (Currently amended) ~~The A compound according to claim 1, selected from the compounds of formula II,~~



wherein

Ar^1, Ar^2 are selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O and S, is selected from the group consisting of phenyl, pyridinyl, quinolinyl, isoquinolinyl, thiophenyl, benzothiadiazolyl, isoxazolyl and oxazolyl,

Ar² is pyridinyl.

R⁶, R⁷ are independently selected from a the meanings given for R⁸, R⁹ and R¹⁰, or R⁶ and R⁷ together form a carbocyclic residue comprising 3 to 7 carbon atoms or a heterocyclic residue comprising 1, 2 or 3 hetero atoms, selected from the group consisting of O, N and S, and 2 to 6 carbon atoms, said carbocyclic or heterocyclic residue being unsubstituted or comprising 1, 2 or 3 substituents, selected from the meanings given for R⁸, R⁹ and R¹⁰; H or A.

E, G, M, Q and U are selected, independently from one another, from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom,

R⁸, R⁹ and R¹⁰ are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH₂Hal, CH(Hal)₂, C(Hal)₃, NO₂, (CH₂)_nCN, (CH₂)_nNR¹¹R¹², (CH₂)_nO(CH₂)_kNR¹¹R¹², (CH₂)_nNR¹¹(CH₂)_kNR¹¹R¹², (CH₂)_nO(CH₂)_kOR¹¹, (CH₂)_nNR¹¹(CH₂)_kOR¹², (CH₂)_nCOOR¹³, (CH₂)_nCOR¹³, (CH₂)_nCONR¹¹R¹², (CH₂)_nNR¹¹COR¹³, (CH₂)_nNR⁸CONR¹¹R¹², (CH₂)_nNR¹¹SO₂A, (CH₂)_nSO₂NR¹¹R¹², (CH₂)_nS(O)_uR¹³, (CH₂)_nOC(O)R¹³, (CH₂)_nCOR¹³, (CH₂)_nSR¹¹, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nCH=N-R¹¹, (CH₂)_nOC(O)NR¹¹R¹², (CH₂)_nNR¹¹COOR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OR¹³, (CH₂)_nN(R¹¹)CH₂CH₂OCF₃,

$(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$,
 $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^8$,
 $(CH_2)_nN(R^8)CH_2CH_2NR^{12}R^8$, $CH=CHCOOR^{13}$,
 $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$,
 $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$,
 $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CH_2CONH_2)COOR^{13}$,
 $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$,
 $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$
 and $(CH_2)_nNCO$, H, A, cycloalkyl comprising 3 to 7 carbon
atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$,
 $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$,
 $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$,
 $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$,
 $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$,
 $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$,
 $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$,
 $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$,
 $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$,
 $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,
 $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{12}$,
 $(CH_2)_nN(R^{11})C(R^{13})HCOOR^{11}$,
 $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{11}$,
 $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, $CH=CHCOOR^{13}$,
 $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$,
 $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$,
 $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$,
 $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$,

$(CH_2)_nN(CH_2CONH_2)COOR^{13}$,
 $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$,
 $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$
and $(CH_2)_nNCO$, wherein

R^{11} , R^{12} are independently selected from the group consisting of H, A, and $(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,


~~R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocyclus which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S,~~

R^{13} , R^{14} are independently selected from the group consisting of H, Hal, A, and $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylencycloalkyl, alkoxy, and alkoxyalkyl and saturated heterocyclyl,

Ar^3 , Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2 , CN, OR^{15} , $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15} , $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

~~Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2 , CN, OR^{15} ,~~



$\text{R}^{15}, \text{R}^{16}$ are independently selected from the group consisting of H, A, and $(\text{CH}_2)_m\text{Ar}^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3 ,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is O or CH_{2x} or $(\text{CHR}^{11})_h\text{-Q-(CHR}^{12})_i$, wherein

Q is selected from a the group consisting of O, S, N-R^{15} , $(\text{CHAl}_2)_j$, $(\text{O-CHR}^{18})_j$, $(\text{CHR}^{18}\text{-O})_j$, $\text{CR}^{18}=\text{CR}^{19}$, $(\text{O-CHR}^{18}\text{CHR}^{19})_j$, $\text{CHR}^{18}\text{CHR}^{19}\text{-O}$, C=O , C=S , C=NR^{15} , $\text{CH(OR}^{15})$, $\text{C(OR}^{15})(\text{OR}^{20})$, C(=O)O , OC(=O) , OC(=O)O , $\text{C(=)N(R}^{15})$, $\text{N(R}^{15})\text{C(=O)}$, $\text{OC(=O)N(R}^{15})$, $\text{N(R}^{15})\text{C(=O)O}$, CH=N-O , CH=N-NR^{15} , OC(O)NR^{15} , $\text{NR}^{15}\text{C(O)O}$, S=O , SO_2 , $\text{SO}_2\text{NR}^{15}$ und $\text{NR}^{15}\text{SO}_2$, wherein

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O, and S, NR^{21} , $\text{C(R}^{22})\text{-NO}_2$, $\text{C(R}^{22})\text{-CN}$ and

$G(CN)_{2r}$, wherein

R^{24} is independently selected from the meanings given for R^{13} ,
 R^{14} , and

R^{22} is independently selected from the meanings given for R^{11} ,
 R^{12} ,

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,






u is 0, 1, 2 or 3,






and


Hal is independently selected from the group consisting of F, Cl,
Br and I;

and pharmaceutically acceptable derivatives, salts and solvates thereof.


4. (Currently Amended) The compound according to claim 1-3, selected from the compounds of formula IIc, ~~IIe~~, ~~IIe~~, ~~IIe~~, ~~IIe~~, IIg, IIh, Ili, IIj, IIk, IIL, IIm, IIn, Ilo, IIp, IIq, IIr, IIs, IIt, IIu, IIv, IIw and IIx,









IIIm




IIIn








IIo




IIp




IIq





IIw



IIx

wherein R^6 , R^7 , R^8 , p , Ar^1 , Y , X , R^9 , R^{10} and q are as defined in claim 3 is 0, 1, 2, 3 or 4, R^{10} is selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^8CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{14}$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^8$, $(CH_2)_nN(R^8)CH_2CH_2NR^{12}R^8$, $CH=CHCOOR^{13}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$,

$(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}$ and $(\text{CH}_2)_n\text{NCO}$, and pharmaceutically acceptable derivatives, salts and solvates thereof.

5. (Currently amended) The compound according to claim 4 3, selected from the compounds (1) to (224) of table 1, the compounds (225) to (449) of table 2 and/or the compounds (450) to (672) of table 3, and pharmaceutically acceptable derivatives, salts and solvates thereof.
6. (Currently amended) The compound according to claim 4 3, selected from the compounds ~~(673) to (758)~~ (673-714), (716)-(731), (733)-(740), (742)-(747), (749), (750), (753), (755), (757) and (758), the compounds ~~(759) to (825)~~ (761)-(765), (768), (770)-(773), (778), (779), (782), (783), (785), (787), (788), (791), (792), (796)-(815), (817)-(819), (822-825) and/or the compounds ~~(826) to (874)~~ (826)-(856), (859)-(864), (869) and (871), and pharmaceutically acceptable derivatives, salts and solvates thereof.
7. (Currently Amended) A medicament comprising the compound according to claim 4 3.
8. (Currently Amended) The compound according to claim 4 3 as a kinase inhibitor.
9. (Previously Presented) The compound according to claim 8, wherein the kinases are selected from raf-kinases.
10. (Currently Amended) A pharmaceutical composition, comprising the compound according to claim 4 3 in a pharmaceutical composition.

11. (Previously Presented) The pharmaceutical composition according to claim 10, wherein it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
12. (Currently Amended) A process for manufacture of a pharmaceutical composition, wherein one or more compounds according to claim 4 3 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients, are processed by mechanical means into a pharmaceutical composition that is suitable as a dosage form for application and/or administration to a patient.
13. (Canceled).
14. (Canceled).
15. (Canceled).
16. (Canceled).
17. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 26, wherein the disorders are selected
from the group consisting of hyperproliferative and nonhyperproliferative disorders.
18. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorder is cancer.

19. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorder is
noncancerous.
20. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorders are selected
from the group consisting of psoriasis, arthritis, inflammation,
endometriosis, scarring, Helicobacter pylori infection, Influenza A,
benign prostatic hyperplasia, immunological diseases, autoimmune
diseases and immunodeficiency diseases.
21. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorders are selected
from the group consisting of melanoma, brain cancer, lung cancer,
squamous cell cancer, bladder cancer, gastric cancer, pancreatic
cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer,
head cancer, neck cancer, oesophageal cancer, gynaecological cancer,
ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid
cancer, lymphoma, chronic leukaemia and acute leukaemia.
22. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorders are selected
from the group consisting of arthritis, restenosis; fibrotic disorders;
mesangial cell proliferative disorders, diabetic nephropathy, malignant
nephrosclerosis, thrombotic microangiopathy syndromes, organ
transplant rejection, glomerulopathies, metabolic disorders,
inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and
neurodegenerative diseases.

23. (Currently Amended) ~~Use according to claim 14, characterised in that~~
The method according to claim 17, wherein the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
24. (Currently Amended) ~~Use of a compound according to claim 4 as a raf-kinase inhibitor.~~ The method according to claim 26, wherein the treatment comprises raf-kinase inhibition.
25. (Currently Amended) ~~Use according to claim 24, characterised in that~~
The method according to claim 28, wherein the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf1.
26. (Currently Amended) A method for the treatment and/or prophylaxis of disorders, wherein one or more compounds according to claim 4 3 is administered to a patient in need of such a treatment.
27. (Previously Presented) A method, comprising, administering to a patient in need thereof the pharmaceutical composition according to claim 10.
28. (Previously Presented) A method for the treatment and/or prophylaxis of disorders comprising, administering to a patient in need thereof the pharmaceutical composition according to claim 10, wherein the disorders are caused, mediated and/or propagated by raf-kinases.

29. (Previously Presented) A method according to claim 28, wherein the disorder is cancerous cell growth mediated by raf-kinase.
30. (Previously Presented) A method for producing compounds of formula II, wherein
- a) a compound of formula III




wherein

FG is a functional group, selected from
 $-N=C=Y$ and $-NH-(C=Y)-LG$,
 wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

- b) with a compound of IV,



wherein

L^2, L^3 are independently from one another H or a metal ion, and R^6, R^7 ,
 $E, G, M, Q, U, R^9, q, X, Ar^2, R^{10}$ and r are as defined in claim 3,

and optionally

- c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.


31. (Previously presented) Compound of formula III,



wherein

FG is a functional group, selected from
 $-N=C=Y$ and $-NH-(C=Y)-LG$,
 wherein Y is as defined as in claim 3 and LG is a leaving group.

32. (Previously presented) Compound of formula IV,



wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^6 , R^7 ,
 E , G , M , Q , U , R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 3.